Piramal Pharma On ADC-Making Edge, BIOSECURE Act, $2Bn-Mark Strategy

 
• By Vibha Ravi
  
Nandini Piramal, Chairperson, Piramal Pharma
Interview with Nandini Piramal, Chairperson, Piramal Pharma

More from Business

More from Financing